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Abstract
Atrial arrhythmia (AA) occurrence in pulmonary arterial hypertension (PAH) may determine clinical deterioration and affect
prognosis. In this study we assessed AA incidence in idiopathic (IPAH) and systemic sclerosis related PAH (SSc-PAH) and evaluated
risk factors, management, and impact on mortality. We collected baseline data from consecutive IPAH or SSc-PAH patients
prospectively enrolled in the Johns Hopkins Pulmonary Hypertension Registry between January 2000 and July 2016. During
follow-up AA onset, treatment, and outcome were recorded. Among 317 patients (201 SSc-PAH, 116 IPAH), 42 developed AA
(19 atrial fibrillation, 10 flutter-fibrillation, 9 atrial flutter, and 4 atrial ectopic tachycardia) with a 13.2% cumulative incidence. Most
events were associated with hospitalization (90.5%). Electrical or pharmacological cardioversion was attempted in most cases.
Patients with AA had higher right atrial pressure, pulmonary wedge pressure (P< 0.005), NT-proBNP (P< 0.05), and thyroid
disease prevalence (P< 0.005). Higher mortality was observed in patients with AA, though not statistically significant (LogRank
P¼ 0.323). Similar long-term mortality between IPAH with AA and SSc-PAH without AA was observed (LogRank P¼ 0.098).
SSc-PAH with AA had the worst prognosis. In PAH patients AA occurrence is a matter of significant concern. Therapeutic
strategies aimed at restoring sinus rhythm may represent an important goal.
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Introduction
Pulmonary arterial hypertension (PAH) is characterized by
a progressive increase in pulmonary vascular resistance
(PVR) leading to chronic right ventricular (RV) pressure
overload.1 Chronic overload of the RV leads to functional
tricuspid regurgitation with a subsequent increase in right
atrial (RA) pressure. The longstanding elevation of atrial
pressure induces progressive atrial dilatation and electro-
physiological remodeling which, in conjunction with auto-
nomic system modulations, may predispose these patients to
the development of atrial arrhythmias (AA).2
The incidence of AA in patients with PAH has not been
well established and scant data exist concerning the
correlation of AA with hemodynamics, clinical parameters,
and clinical consequences in these patients.3–7 While most of
the prior studies include more heterogeneous patient popu-
lations, limiting the ability to generalize to the PAH
population, they suggest that AA occurrence may have
prognostic implications.3–5,7 RA function contributes
importantly to right heart function in patients with PAH
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as intact atrioventricular synchrony optimizes biventricular
ﬁlling and is an important determinant of systemic output in
patients with RV compromise.5,8 Despite growing evidence
of the negative impact of AA on patients with pulmonary
hypertension (PH), the clinical impact and optimal manage-
ment approach in PAH remain undeﬁned.
In this study we sought to verify the hypothesis that
development of AA would negatively impact the clinical
course of PAH. We describe the incidence of AA (speciﬁc-
ally, atrial ﬁbrillation, atrial ﬂutter, or atrial ectopic tachy-
cardia) in patients with PAH and explore the possible
correlations between the onset of AA and baseline hemo-
dynamics, co-morbidities, 6-min walk distance (6MWD),
and serum biomarkers. We also aimed at assessing the
impact on long-term mortality. Additionally, given our
unique patient population, we compared the impact of AA
on morbidity and mortality in idiopathic (IPAH) versus sys-
temic sclerosis (SSc) related PAH (SSc-PAH).
Methods
Patient population
This prospective cohort study was approved by the Johns
Hopkins University Institutional Review Board
(NA_00027124, Baltimore, MD, USA); informed consent
was obtained for all patients. The study was conducted in
accordance with the Declaration of Helsinki. Consecutive
patients with either IPAH or SSc-PAH evaluated at the
Johns Hopkins Pulmonary Hypertension Program between
January 2000 and July 2016, with at least six months of
follow-up, were included. A diagnosis of PAH was con-
ﬁrmed by right heart catheterization (RHC) at rest and
deﬁned as the presence of mean pulmonary arterial pressure
(mPAP) 25mmHg, pulmonary artery wedge pressure
(PAWP) 15mmHg, and PVR> 3 Wood units (WU).9 All
patients with other potential causes of PH, including con-
genital heart disease, human immunodeﬁciency virus, por-
topulmonary hypertension, left heart disease (LHD),
signiﬁcant chronic obstructive pulmonary disease or inter-
stitial lung disease, chronic thromboembolic disease, and
sickle cell disease were excluded. The diagnosis of SSc was
based on speciﬁc criteria as previously reported10 and all
diagnoses were conﬁrmed by rheumatologists with expertise
in SSc.
Data collection
Data were collected prospectively in the Johns Hopkins
Pulmonary Hypertension Registry. Baseline demographics,
hemodynamics, medical history, and World Health
Organization (WHO) functional class (FC), 6MWD accord-
ing to the recommendations of the American Thoracic
Society,11 and hemodynamics by RHC were obtained.
Hemodynamic data included: right atrial pressure (RAP),
mPAP, PAWP, cardiac output, and PVR. Baseline
electrocardiography was performed in all patients. Serum
measurements of N-terminal pro B type natriuretic peptide
(NT-proBNP), creatinine, and uric acid were obtained. All
patients underwent regular follow-up visit every three, six,
and 12 months or when clinically indicated. During follow-
up visits, medical history, physical examination, WHO FC,
and details concerning any interim hospitalizations and
alterations in treatment were recorded.
The arrhythmias considered were atrial ﬁbrillation, atrial
ﬂutter, and atrial ectopic tachycardia detected on electrocar-
diography. Treatment was individualized and dictated by
the treating physician; however, a rhythm control strategy
was adopted and applied in the majority of our patients
whenever feasible and clinically indicated. For the purpose
of this study, sinus rhythm was considered stable when it
was maintained for the entire follow-up period. Initial treat-
ment included pharmacologic cardioversion, direct current
cardioversion, and electrophysiological study with radiofre-
quency ablation. When these interventions were not success-
ful at restoring sinus rhythm, rate control strategy was
prescribed (primarily digoxin or diltiazem). According to
guidelines, anticoagulation therapy was prescribed to all
patients who experienced AA, unless contraindicated.12
The primary outcome was all-cause mortality. Survival
was assessed from the date of diagnostic RHC.
Statistical analysis
Continuous variables were expressed as mean standard
deviation and categorical variables were expressed as
number or percentages. Group comparisons were performed
using independent sample t test or Mann–Whitney non-
parametrical analysis for continuous variables and 2
statistics for categorical variables, as appropriate. Survival
analysis was performed by means of Cox regression
model, log-rank test, and Kaplan–Meier survival curves.
A P value< 0.05 was considered signiﬁcant. Statistical ana-
lysis was performed using SPSS version 22.0 (IBM Corp.,
Armonk, NY, USA).
Results
Study population and incidence of AA
A total of 317 consecutive patients who met the inclusion
criteria were enrolled. During the mean follow-up period
of 67 51 months, 42 patients developed AA, with a
cumulative incidence of 13.2%. This incidence was
slightly higher in the SSc-PAH group, though this did
not reach statistical signiﬁcance (12.1% in IPAH vs.
13.9% in SSc-PAH, P¼NS). Table 1 shows the baseline
characteristics of the overall patient population and a com-
parison between patients who did and did not develop AA.
Aside from a higher prevalence of male sex in patients with
AA, the two groups did not diﬀer signiﬁcantly in regard to
demographics.
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Similar co-morbidities and risk factors for cardiopulmon-
ary disease were present, with the exception of a signiﬁcantly
higher prevalence of thyroid disease, deﬁned as either hypo
or hyperthyroidism, or radiological evidence of thyroid nod-
ules, in the AA group.
Right and left heart filling pressures are higher in patients
with PAH who develop AA
In terms of baseline hemodynamic measurements and
biomarkers, as shown in Table 2, patients with AA had
signiﬁcantly higher right and left heart ﬁlling pressures
(RAP and PAWP), though they had similar RV afterload
(PVR¼ 9.4 5.8 WU vs. 9.3 5.9 WU, P¼NS).
NT-proBNP measured at baseline was higher in patients
who developed AA in comparison to patients without AA
(Table 2). 6MWD did not diﬀer signiﬁcantly between the
two groups. The majority of patients (94.6%) were being
treated with pulmonary vasodilator drugs (prostanoids,
phosphodiesterase 5 inhibitors, endothelin receptor antag-
onists, or calcium channel blockers), either in monotherapy
or in combination therapy, and there was no diﬀerence in
treatment between groups (Table 2).
AA occurrence determines clinical worsening in patients
with PAH
In most cases (90.1%), the onset of AA resulted in clin-
ical worsening with signs of RV failure requiring hospital-
ization (Table 1). In particular, 15 patients needed
vasopressor support (mainly dopamine) and 14 of them
(36.8%) were admitted to the medical intensive care unit
(Table 1). Related symptoms were worsening of exertional
dyspnea, palpitations, and peripheral edema. The most
common type of arrhythmia was atrial ﬁbrillation
(19 patients), followed by ﬂutter-ﬁbrillation (ten patients),
atrial ﬂutter (nine patients), and atrial ectopic tachy-
cardia (four patients). Most of the patients with AA under-
went at least one attempt at conversion to sinus rhythm. In
64.3% of cases, a second episode or a recurrence of AA
occurred. Overall, 34 episodes of atrial ﬁbrillation, 18
of atrial ﬂutter, and ﬁve of atrial ectopic tachycardia
have been observed. Among PAH patients who developed
AA, 36% of them (nine IPAH and six SSc-PAH) were
already on anticoagulation before AA occurrence. Details
concerning the treatment of patients with AA are found in
Table 3.
Table 1. Clinical characteristics of the study population.
All PAH PAH without AA PAH with AA P value
Patients (n) 317 275 42
Female (n (%)) 266 (83.9%) 236 (85.8%) 30 (71.4%) 0.02
Race White/Black/other (n) 240/68/9 208/60/7 32/8/2 ns
Age at diagnosis (years) 56.7 14.4 56.3 14.7 59.0 12.1 0.047
BMI (kg/m2) 27.9 7.1 28.0 7.3 27.4 6.4 ns
Coronary artery disease (n (%)) 19 (6) 16 (5.8) 3 (7.1) ns
Systemic hypertension (n (%)) 95 (30) 84 (30.5) 11 (26.2) ns
Smoking status (284 patients):
never/former/active (n (%))
141/118/25
(49.6/41.6/8.8)
121/99/22
(50/40.9/9.1)
20/19/3
(47.6/45.2/7.1)
ns
Diabetes mellitus (n) 21 (6.6) 18 (6.5) 3 (7.1) ns
Dyslipidemia (303 patients) (n) 94 (31) 83 (31.8) 11 (26.2) ns
Cerebrovascular disease (302 pts), n 15 (5) 12 (4.6) 3 (7.1) ns
Obstructive sleep apnea (n) 33 (10.4) 29 (10.5) 4 (9.5) ns
Chronic obstructive pulmonary disease (n) 11 (3.5) 10 (3.6) 1 (2.5) ns
Thyroid disease (n (%)) 146 (46.1) 117 (42.5) 29 (69) 0.001
Hypothyroidism/hyperthyroidism/
thyroid nodules (n (%))
124/13/9 (84.9/8.9/6.2) 100/10/7 (85.5/8.5/6) 24/3/2 (82.8/10.3/6.9) ns
Hospitalization for AA onset (n (%)) NA NA 38 (90.1) NA
Hospitalization in MICU for AA onset (n) NA NA 14 NA
Vasopressor use during hospitalization (n) NA NA 15 NA
Data are presented as mean standard deviation, number, or percentage.
Comparison between groups (PAH without AA vs. PAH with AA) was made with independent sample t-test or Mann–Whitney non-parametrical analysis for
continuous variables and 2 statistics for categorical variables, as appropriate, and a P value< 0.05 was considered significant.
PAH, pulmonary arterial hypertension; AA, atrial arrhythmias; BMI, body mass index; NA, not applicable; MICU, medical intensive care unit.
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Table 2. PAH etiology, functional class, pulmonary vasodilator treatment, hemodynamics, and serum measurements of the study population at
baseline.
All PAH PAH without AA PAH with AA P value
Patients (n) 317 275 42
PAH etiology
Idiopathic PAH (n (%)) 116 102 (87.9) 14 (12.1) ns
Scleroderma related PAH (n (%)) 201 173 (86.1) 28 (13.9) ns
WHO FC (276 patients) (n) I/II/III/IV 13/103/140/20 12/90/120/18 1/13/20/2 ns
6MWD (m) 327.6 128.6 331.4 127.2 305.0 136.4 ns
PAH treatment (300 patients)
PDE-5 inhibitor (n) 258 220 38 ns
Endothelin receptor antagonist (n) 206 175 31 ns
Prostacyclin analogue (n) 122 104 18 ns
Calcium channel blocker (n (%)) 4 (1.3) 3 (1.1) 1 (2.4) ns
Monotherapy (n (%)) 84 (28) 76 (29.3) 8 (19.5) ns
Dual therapy (n (%)) 128 (42.7) 111 (42.9) 17 (41.5) ns
Triple therapy (n (%)) 88 (29.3) 72 (27.8) 16 (39) ns
Hemodynamic parameters
Heart rate (bpm) 82 14 82 14 83 16 ns
Right atrial pressure (mmHg) 9.3 5.9 8.9 5.7 12.3 6.1 0.002
Mean pulmonary arterial pressure (mmHg) 45.5 14 45.3 14.0 47.3 14.3 ns
Pulmonary wedge pressure (mmHg) 10.6 4.0 10.3 3.9 12.4 3.8 0.002
Cardiac output (L/min) 4.37 1.56 4.42 1.57 4.02 1.47 ns
Pulmonary vascular resistance (WU) 9.4 5.8 9.3 5.9 9.9 5.4 ns
Serum measurements
NT-proBNP (pg/mL) 2071 3688 1866 3711 3168 3398 0.046
Creatinine (mmol/L) 1.01 0.48 1.01 0.51 1.03 0.33 ns
Uric acid (mmol/L) 7.1 2.46 7.02 2.42 7.58 2.71 ns
Data are presented as mean standard deviation, number, or percentage.
Comparison between groups (PAH without AA vs. PAH with AA) was made with independent sample t-test or Mann–Whitney non-parametrical analysis for
continuous variables and 2 statistics for categorical variables, as appropriate, and a P value< 0.05 was considered significant.
PAH, pulmonary arterial hypertension; AA, atrial arrhythmias; WHO, World Health Organization; PDE-5, phosphodiesterase 5; WU, Wood Units; NT-proBNP,
N-terminal pro b type natriuretic peptide.
Table 3. Type and treatment of AA SVA in PAH patients.
Total AA
(42 patients)
Transient AA
(15 patients)
Recurrent or
permanent AA
(27 patients)
Atrial fibrillation (n of episodes) 34 9 25 (6 permanent)
Atrial flutter (n of episodes) 18 4 14
Atrial ectopic tachycardia (n of episodes) 5 2 3
Anticoagulation therapy (n of patients) 37 13 24
Direct current cardioversion (n of patients) 13 3 10
EPS and ablation (n of patients) 13 2 11
Amiodarone (n of patients) 19 5 14
Digoxin (n of patients) 24 8 16
Metoprolol or Carvedilol (n of patients) 18 6 12
Verapamil or Diltiazem (n of patients) 18 6 12
Flecainide (n of patients) 1 0 1
AA, atrial arrhythmia; PAH, pulmonary arterial hypertension; EPS, electrophysiological study.
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Survival analysis
Among the overall PAH population, a total of 170 (53.6%)
deaths were observed: 141 (51.3%) in the group without AA
and 29 (69%) in the group with AA. Kaplan–Meier survival
curves are shown in Figs. 1 and 2. Patients with AA had a
higher but not statistically signiﬁcant long-term mortality in
comparison to patients without AA (Log Rank P¼ 0.323).
Etiology-based analysis revealed that patients with SSc-
PAH, both with and without AA, had a signiﬁcantly
worse prognosis when compared to IPAH patients (SSc-
PAH without AA vs. IPAH without AA Log Rank
P< 0.001; SSc-PAH with AA vs. IPAH with AA: Log
Rank P¼ 0.031). Interestingly, the mortality between SSc-
PAH patients without AA and IPAH patients with AA was
not statistically diﬀerent (Log Rank P¼ 0.098), as shown in
Fig. 2. These results were conﬁrmed by the Cox regression
univariate and multivariate analysis, adjusted for age, sex,
and thyroid function (Table 4). Patients with SSc-PAH who
developed AA had the worst long-term prognosis. Survival
between patients on anticoagulation before AA versus
patients not on anticoagulation was not signiﬁcantly diﬀer-
ent (Log rank test P¼ 0.794).
Discussion
This study demonstrates that AA are common in a cohort of
317 PAH patients, with a cumulative incidence of 13.2%
during the ﬁve years of follow-up. In the existing literature,
the incidence of AA in patients with PH has been reported
to be in the range of 10–25% with a mean six years of
follow-up.2,3,5–7,13–16 Importantly, we believe our reported
incidence of AA is particularly accurate for these speciﬁc
PAH etiologies (SSc-PAH and IPAH), given the fact that
most of the previous studies included patients with hetero-
geneous etiologies of PH, including both pre- and post-
capillary hypertension. Prior studies frequently included
patients with PH due to LHD, thus demonstrating, as
Fig. 2. Kaplan–Meier curves for all-cause mortality among PAH
patients according to the etiology and the occurrence of AA. P value
SSc-PAH with AA vs. SSc-PAH without AA: Log Rank P¼ 0.454; IPAH
with AA vs. IPAH without AA: Log Rank P¼ 0.410; SSc-PAH without
AA vs. IPAH without AA: Log Rank P< 0.001; SSc-PAH with AA vs.
IPAH with AA: Log Rank P¼ 0.031; SSc-PAH without AA vs. IPAH with
AA: Log Rank P¼ 0.098; SSc-PAH with AA vs. IPAH without AA: Log
Rank P< 0.001.
PAH, pulmonary arterial hypertension; AA, atrial arrhythmias; IPAH,
idiopathic pulmonary arterial hypertension; SSc-PAH, systemic scler-
osis related pulmonary arterial hypertension.
Fig. 1. Kaplan–Meier curves for all-cause mortality among PAH
patients according to the occurrence of AA. P value PAH with AA vs.
PAH without AA: Log Rank P¼ 0.323; Breslow P¼ 0.985; Tarone-
Ware P¼ 0.717.
PAH, pulmonary arterial hypertension; AA, atrial arrhythmia.
Table 4. Cox regression analysis for all-cause mortality among PAH
patients according to the etiology and the occurrence of AA in a
univariate model and in a multivariate model, adjusted for age, sex, and
thyroid dysfunction.
Univariate analysis Multivariate analysis*
Hazard ratio P value Hazard ratio P value
SSc-PAH with AA Ref – Ref –
SSc-PAH without AA 0.864 0.550 0.906 0.699
IPAH with AA 0.500 0.099 0.565 0.184
IPAH without AA 0.364 <0.001 0.403 0.003
*Adjusted for age, sex, and thyroid dysfunction.
SSc-PAH, systemic sclerosis related pulmonary arterial hypertension; AA, atrial
arrhythmia; IPAH, idiopathic pulmonary arterial hypertension.
The P values statistically significant are highlighted in bold
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expected, a higher prevalence of arrhythmias2,14–16 in a con-
dition with a distinct pathophysiology and possible con-
founding factors warranting evaluation as a separate
entity from PAH.
In our study, the occurrence of AA was associated with
higher pressures in both atria (the right and, as suggested by
PAWP, the left), as well as higher levels of NT-proBNP. In
addition, the presence of thyroid disease was signiﬁcantly
associated with the development of AA. A higher prevalence
of thyroid disease has been described in patients with
PAH,17–19 and, although the reason for this association is
not completely characterized, the current results suggest that
the presence of thyroid disease may aﬀect prognosis.20 In
our cohort, survival analysis revealed that patients who
developed AA without thyroid dysfunction had a signiﬁ-
cantly worse prognosis in comparison to patients without
AA and without thyroid dysfunction (Log rank P¼ 0.048).
The worst prognosis was observed in patients who devel-
oped AA that was not related to the presence of thyroid
dysfunction. These results suggest that AA associated with
thyroid dysfunction may be a relatively benign condition,
while, on the contrary, AA unrelated to thyroid dysfunction
may adversely aﬀect prognosis in PAH patients.
In most cases, AA onset manifested as clinical worsening,
leading to progressive symptoms of right heart failure and to
hospitalization. In patients with PH, the loss of adequate
atrial contraction, atrioventricular synchrony, and heart
rate control progressively compromises global cardiac func-
tion, impacting morbidity and mortality. In normal individ-
uals, longitudinal RV shortening accounts for
approximately 70% of global RV function, with the remain-
der accounted for by RA function. When RV function is
impaired, as seen in PAH, the RA accounts for a signiﬁ-
cantly larger proportion of global right heart function as
measured by tricuspid annular plane systolic excursion
(TAPSE). Augmented RA contraction enhances ﬁlling of
the non-compliant RV and is essential for maintaining car-
diac output. In a recent study evaluating PAH patients with
echocardiogram, mean TAPSE was 1.7 cm and could have
dropped as low as 0.8 cm in the absence of RA systolic func-
tion.21 This diﬀerence illustrates the importance of RA func-
tion in total right heart function in patients with PAH,
providing physiologic rationale for why AA are so poorly
tolerated in these patients. In addition, this supports prior
data demonstrating that increased RA size is a powerful
predictor of mortality in PAH, suggesting RA size may cor-
relate with RA dysfunction and represent a greater burden
of total right heart dysfunction.22–24 Therefore, while in
patients without PAH the RA is often described as a reser-
voir, storing blood when the tricuspid valve is closed, and a
conduit, passively transferring blood into the right ventricle,
in patients with PAH the most crucial role of the RA may be
its pump function, with atrial systole adding substantially to
RV ﬁlling and function. Losing this function with the onset
of AA in patients with PAH should indeed be interpreted as
a threatening sign. A rhythm control strategy is quite
appropriate in LHD. However, in PAH most experts
would agree that development of atrial ﬁbrillation causes
signiﬁcant hemodynamic instability as these patients are
for homeostasis on an adequate atrial kick.21 Therefore,
our initial strategy has always been to restore a sinus
rhythm as the ﬁrst therapeutic maneuver.
Prior studies suggest a causal relationship between devel-
opment of AA and clinical deterioration in patients with
PH.5–7,9 Indeed, restoration of sinus rhythm was followed
by clinical improvement, and the development of permanent
AA, but not transient AA, was associated with increased
mortality in patients with PH. Importantly, our work sup-
ports this concept in the PAH population. There was no
signiﬁcant diﬀerence in 6MWD, FC, and RV afterload
between groups, which suggests AA is not merely a
marker of disease severity. Further, we found that AA
occurrence, particularly if recurrent or persistent, is asso-
ciated with worse long-term prognosis. Together, these
observations suggest AA occurrence in PAH may be an
independent cause of clinical decline leading to increased
morbidity and mortality.
Furthermore, analyzing the impact of AA on mortality
according the etiology of PAH (IPAH vs. SSc-PAH) high-
lighted another important result. It is well-known that
among the many diﬀerent etiologies of PAH, IPAH has a
better long-term median survival (eight years), while the
prognosis with SSc-PAH is one of the worst, with a
median survival of less than four years.1,25,26 As shown in
our analysis, IPAH patients with AA had a long-term mor-
tality similar to the SSc-PAH patients without AA.
Scleroderma heart disease is classiﬁed into primary and sec-
ondary forms. In primary SSc cardiac disease, there is direct
involvement of the myocardium, pericardium, valves, cor-
onary vessels, and conduction system due to vascular, ﬁbro-
tic, and inﬂammatory changes of the disease itself.
Secondary cardiac involvement develops in response to pul-
monary vascular or interstitial lung disease. In primary
SSc cardiac disease, the presence of focal ﬁbrosis is the pre-
dominant pathologic ﬁnding – ﬁbrosis of the conduction
system can result in various types of heart block and/or
arrhythmias. Interestingly, in our study, the incidence of
atrial arrhythmias was similar in IPAH and SSc-PAH.
The reason for the substantial prognostic diﬀerences
between IPAH and SSc-PAH is poorly understood,
but the signiﬁcant diﬀerence in outcome with the
development of AA supports the hypothesis that it is related
to the burden of right heart disease with impaired ability of
the right heart to adapt to elevated pulmonary vascular
pressures in the absence of atrial systole.27 In addition,
there was no signiﬁcant diﬀerence in RV load between
groups (Table 2), further suggesting that prognosis is not
directly related to the magnitude of RV afterload, but
rather the ability of the RA and RV to adapt to that pro-
gressive change in afterload. By itself, myocardial involve-
ment in SSc imparts an unfavorable prognosis with an
overall ﬁve-year mortality of approximately 70%. Perhaps
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not surprisingly, patients with SSc-PAH and AA had the
worst prognosis.
Study limitations
There are some study limitations that need to be taken into
account. First, since there was no routine electrocardio-
graphic monitoring, if arrhythmias were asymptomatic,
some AA could be missed, thus leading to an underestima-
tion of true incidence. Second, the presence of higher PAWP
in patients with AA could indicate that some of these
patients might have occult LHD (heart failure with pre-
served ejection fraction). While we are unable to fully
characterize this diﬀerence between groups, there was
importantly no diﬀerence in recorded risk factors for
LHD (systemic hypertension, diabetes, coronary artery dis-
ease). Third, this was a single-center experience with
unequal sample sizes between IPAH and SSc-PAH, which
merely reﬂects referral bias to our program. As the analysis
between IPAH and SSc-PAH is based on small and
unmatched patient populations, interesting trends can be
observed but deﬁnitive conclusions cannot be made.
Furthermore, the present study did not compare the dif-
ferent treatments of AA, and thus optimal treatment of
these patients remains elusive and requires further investi-
gation. Restoration and maintenance of sinus rhythm
appear to be of mechanistic importance for preserving RV
function and are important treatment objectives in this fra-
gile patient population. However, optimal medical therapy
remains unclear, since most of the existing
anti-arrhythmic agents have relevant side eﬀects or contra-
indications in patients with PAH. In addition, electro-
physiological and anatomic mapping of the RA in patients
with IPAH highlights the presence of RA electrical tissue
remodeling, as patients were found to have prolongation of
sinus node recovery times, reduction in tissue voltage with
an increase in electrically silent areas, increased complex
fractionated activity, and atrial conduction slowing.2
A recognition of these changes associated with longstanding
PAH is critical to understanding why response to pharma-
cologic and catheter-based strategies to restore and maintain
sinus rhythm may be associated with lower success than in
control patients without PAH who develop AA.28 However,
despite the robust myocardial remodeling observed in these
patients, limited data suggest that this approach is feasible,
safe, and eﬀective in this patient population.28–30 Given the
overall tenuous clinical status of these patients, long periods
of atrial arrhythmia are likely to be detrimental to clinical
stability and long-term outcomes, and pursuing ablation
may be clinically beneﬁcial for this patient population.
Conclusion
In conclusion, the onset of AA in patients with PAH is a
clinically relevant issue. The occurrence of AA is associated
with high morbidity and mortality, particularly if recurrent
or persistent, highlighting the importance of atrial systole,
atrioventricular synchrony, and heart rate control to total
right heart function in this patient population. Interestingly,
the survival of patients with IPAH, typically better in com-
parison to other forms of PAH, becomes comparable to that
of SSc-PAH patients in the presence of AA, suggesting atrial
arrhythmias are not only a cause of clinical decline but also
a marker of progressive right heart disease. Further studies
are needed to deﬁne the best approach to arrhythmia man-
agement in PAH.
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